Diagnostic significance of dysregulated miRNAs in T-cell malignancies and their metabolic roles.
MicroRNAs
T-cell malignancies
diagnosis
lymphomas
metabolism
prognosis
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
28
05
2023
accepted:
17
07
2023
medline:
28
8
2023
pubmed:
28
8
2023
entrez:
28
8
2023
Statut:
epublish
Résumé
T-cell malignancy is a broad term used for a diverse group of disease subtypes representing dysfunctional malignant T cells transformed at various stages of their clonal evolution. Despite having similar clinical manifestations, these disease groups have different disease progressions and diagnostic parameters. The effective diagnosis and prognosis of such a diverse disease group demands testing of molecular entities that capture footprints of the disease physiology in its entirety. MicroRNAs (miRNAs) are a group of noncoding RNA molecules that regulate the expression of genes and, while doing so, leave behind specific miRNA signatures corresponding to cellular expression status in an altered stage of a disease. Using miRNAs as a diagnostic tool is justified, as they can effectively distinguish expressional diversity between various tumors and within subtypes of T-cell malignancies. As global attention for cancer diagnosis shifts toward liquid biopsy, diagnosis using miRNAs is more relevant in blood cancers than in solid tumors. We also lay forward the diagnostic significance of miRNAs that are indicative of subtype, progression, severity, therapy response, and relapse. This review discusses the potential use and the role of miRNAs, miRNA signatures, or classifiers in the diagnosis of major groups of T-cell malignancies like T-cell acute lymphoblastic lymphoma (T-ALL), peripheral T-cell lymphoma (PTCL), extranodal NK/T-cell lymphoma (ENKTCL), and cutaneous T-cell lymphoma (CTCL). The review also briefly discusses major diagnostic miRNAs having prominent metabolic roles in these malignancies to highlight their importance among other dysregulated miRNAs.
Identifiants
pubmed: 37637043
doi: 10.3389/fonc.2023.1230273
pmc: PMC10448964
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1230273Informations de copyright
Copyright © 2023 Mondal, Shinde, Paul, Thakur, Velu, Tiwari, Dixit, Amit, Vishvakarma and Shukla.
Déclaration de conflit d'intérêts
Authors ST and GV were employed by the company Trivitron Healthcare Pvt. Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Diabetologia. 2014 Jan;57(1):122-8
pubmed: 24149837
Int J Mol Sci. 2019 Jun 20;20(12):
pubmed: 31226848
Blood. 2011 Dec 22;118(26):6881-92
pubmed: 22042699
Oncotarget. 2016 Nov 29;7(48):78667-78679
pubmed: 27637078
Leuk Lymphoma. 2014 Apr;55(4):957-8
pubmed: 23772646
PLoS One. 2014 Mar 20;9(3):e92585
pubmed: 24651162
Proc (Bayl Univ Med Cent). 2002 Oct;15(4):433-6
pubmed: 16333475
Clin Exp Immunol. 2018 Feb;191(2):166-179
pubmed: 28987000
Leukemia. 2022 Jul;36(7):1720-1748
pubmed: 35732829
Blood. 1994 Sep 1;84(5):1361-92
pubmed: 8068936
Blood Cancer J. 2014 Nov 07;4:259
pubmed: 25382608
Oncol Lett. 2022 May 27;24(1):228
pubmed: 35720506
Blood Adv. 2017 May 04;1(12):733-747
pubmed: 29296717
Oncogene. 2018 May;37(22):2982-2991
pubmed: 29527004
Br J Surg. 2018 Jan;105(1):75-85
pubmed: 29116653
Clin Chem. 2010 Nov;56(11):1733-41
pubmed: 20847327
J Exp Clin Cancer Res. 2019 Feb 15;38(1):81
pubmed: 30770776
Hematology. 2023 Dec;28(1):2196857
pubmed: 37014739
Blood. 2013 Sep 19;122(12):2083-92
pubmed: 23801630
Cancer Treat Rev. 2020 Dec;91:102106
pubmed: 33049623
Blood. 2011 Nov 3;118(18):4919-29
pubmed: 21921041
Onco Targets Ther. 2018 Nov 13;11:8025-8032
pubmed: 30519044
Am J Pathol. 2014 Apr;184(4):1185-97
pubmed: 24655378
Cell Death Dis. 2011 Apr 28;2:e151
pubmed: 21525938
Cancers (Basel). 2021 Nov 22;13(22):
pubmed: 34831008
Ther Adv Med Oncol. 2018 Aug 29;10:1758835918794630
pubmed: 30181785
Science. 2016 Oct 28;354(6311):481-484
pubmed: 27708054
J Ovarian Res. 2021 Jan 8;14(1):8
pubmed: 33419459
Trends Endocrinol Metab. 2013 Jul;24(7):361-73
pubmed: 23602813
Haematologica. 2014 Jan;99(1):116-24
pubmed: 23975180
Nat Genet. 2011 Jun 05;43(7):673-8
pubmed: 21642990
Blood. 2018 Feb 15;131(7):759-770
pubmed: 29208599
J Cell Physiol. 2019 Aug;234(8):13182-13190
pubmed: 30536619
PLoS One. 2018 Jun 12;13(6):e0198477
pubmed: 29894486
Cancer Cell Int. 2021 Nov 27;21(1):629
pubmed: 34838007
Carcinogenesis. 2020 Jul 14;41(7):972-983
pubmed: 31628462
Cancer Res. 2009 May 15;69(10):4443-53
pubmed: 19435910
Br J Dermatol. 2022 Nov;187(5):815-817
pubmed: 35791764
Mol Cancer. 2018 Jan 24;17(1):12
pubmed: 29368647
J Invest Dermatol. 2018 Sep;138(9):2024-2032
pubmed: 29559342
EJHaem. 2021 May 12;2(3):616-627
pubmed: 35844685
Am J Pathol. 2015 May;185(5):1487-99
pubmed: 25907832
Blood Rev. 2018 Nov;32(6):457-472
pubmed: 29703513
Mol Oncol. 2011 Jun;5(3):273-80
pubmed: 21406335
Cancers (Basel). 2021 Jun 10;13(12):
pubmed: 34200751
Cancers (Basel). 2019 Nov 20;11(12):
pubmed: 31756931
Front Oncol. 2023 Apr 14;13:1141108
pubmed: 37124514
J Clin Oncol. 2008 Sep 1;26(25):4124-30
pubmed: 18626005
Genes Dis. 2020 Aug 31;8(5):590-602
pubmed: 34291131
Oncotarget. 2016 Oct 4;7(40):65454-65470
pubmed: 27589845
Lipids Health Dis. 2020 Apr 16;19(1):76
pubmed: 32299444
Cancers (Basel). 2020 Nov 27;12(12):
pubmed: 33261029
Nutr Metab (Lond). 2018 Oct 1;15:68
pubmed: 30302122
Heliyon. 2022 Mar 05;8(3):e09068
pubmed: 35284668
J Genet Eng Biotechnol. 2021 Oct 5;19(1):147
pubmed: 34611771
Exp Hematol Oncol. 2013 Apr 08;2(1):10
pubmed: 23566596
FEBS Open Bio. 2016 Feb 27;6(4):251-63
pubmed: 27239439
Hum Pathol. 2013 Jun;44(6):1011-6
pubmed: 23260326
Adv Biol Regul. 2019 Dec;74:100650
pubmed: 31548132
Sci Rep. 2017 Aug 11;7(1):7901
pubmed: 28801656
EBioMedicine. 2020 Dec;62:103100
pubmed: 33161226
PLoS One. 2017 Nov 13;12(11):e0187722
pubmed: 29131834
Int J Mol Sci. 2018 Sep 20;19(10):
pubmed: 30241379
Blood. 1998 Aug 15;92(4):1150-9
pubmed: 9694702
Front Endocrinol (Lausanne). 2022 Jan 03;12:750261
pubmed: 35046889
Mol Med. 2021 Sep 6;27(1):101
pubmed: 34488621
Clin Lymphoma Myeloma. 2009;9 Suppl 3:S214-21
pubmed: 19778844
Anal Chem. 2019 Mar 5;91(5):3179-3186
pubmed: 30702270
J Neurooncol. 2013 Feb;111(3):273-83
pubmed: 23263745
Blood. 2011 Nov 24;118(22):5891-900
pubmed: 21865341
BMC Cancer. 2014 Jun 16;14:443
pubmed: 24935220
Cell. 2012 Mar 16;148(6):1172-87
pubmed: 22424228
Blood. 2010 Aug 19;116(7):1105-13
pubmed: 20448109
Int J Hematol. 2019 Jan;109(1):5-17
pubmed: 30145780
Metabolites. 2023 Mar 09;13(3):
pubmed: 36984849
Mol Cancer. 2022 Dec 22;21(1):226
pubmed: 36550553
Mol Ther Oncolytics. 2020 May 23;17:509-517
pubmed: 32577500
Ann Med Surg (Lond). 2022 Nov 09;84:104844
pubmed: 36536747
Am J Physiol Endocrinol Metab. 2016 May 15;310(10):E828-37
pubmed: 26956185
Neoplasia. 2019 Mar;21(3):294-310
pubmed: 30763910
PLoS One. 2019 Oct 24;14(10):e0224305
pubmed: 31648231
Blood. 2017 Mar 2;129(9):1059-1060
pubmed: 28115370
Proc Natl Acad Sci U S A. 2015 Dec 1;112(48):14924-9
pubmed: 26627242
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2020 Apr;28(2):436-441
pubmed: 32319375
Front Endocrinol (Lausanne). 2018 Aug 03;9:402
pubmed: 30123182
Dis Markers. 2010;29(5):251-8
pubmed: 21206010
Anticancer Res. 2015 Apr;35(4):2055-61
pubmed: 25862860
Front Cell Dev Biol. 2021 Nov 23;9:755776
pubmed: 34888308
Turk J Pediatr. 2001 Apr-Jun;43(2):105-9
pubmed: 11432485
J Cancer Res Clin Oncol. 2020 Aug;146(8):2051-2066
pubmed: 32462295
Dev Cell. 2008 Aug;15(2):261-71
pubmed: 18694565
Database (Oxford). 2020 Jan 1;2020:
pubmed: 32128558
Am J Transl Res. 2020 Sep 15;12(9):4873-4884
pubmed: 33042395
Clin Cancer Res. 2021 Nov 1;27(21):6039-6053
pubmed: 34426436
Biomed Pharmacother. 2018 Jul;103:1194-1201
pubmed: 29864898
Transl Lung Cancer Res. 2023 Mar 31;12(3):594-614
pubmed: 37057121
J Hematol Oncol. 2022 Sep 12;15(1):131
pubmed: 36096847
Cancer. 2014 Jul 1;120(13):1993-9
pubmed: 24706502
Oncol Rep. 2012 Oct;28(4):1346-52
pubmed: 22895557
J Virol. 2012 Jun;86(12):6889-98
pubmed: 22496226
Cancer Treat Res. 2019;176:83-98
pubmed: 30596214
J Hematol Oncol. 2019 Apr 2;12(1):33
pubmed: 30935402
Diabetes. 2017 Dec;66(12):3029-3040
pubmed: 28970284
Blood. 2014 May 8;123(19):2915-23
pubmed: 24632715
Proc Natl Acad Sci U S A. 2010 Sep 14;107(37):16228-33
pubmed: 20805506
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Biomed Pharmacother. 2017 Aug;92:1119-1127
pubmed: 28622713
Oncotarget. 2020 Jun 30;11(26):2464-2483
pubmed: 32655834
Blood. 2011 Jun 16;117(24):6627-37
pubmed: 21471522
Hematol Rep. 2017 Sep 27;9(3):7088
pubmed: 29071053
Acta Derm Venereol. 2019 Nov 1;99(12):1148-1153
pubmed: 31453630
Int J Oncol. 2016 Feb;48(2):577-86
pubmed: 26648284
Cell Death Dis. 2022 Dec 9;13(12):1032
pubmed: 36494333
Front Oncol. 2021 Mar 18;11:658234
pubmed: 33816315
Am J Cancer Res. 2016 Jan 15;6(2):312-20
pubmed: 27186405
Medicina (Kaunas). 2021 May 15;57(5):
pubmed: 34063545
NPJ Precis Oncol. 2021 Jul 2;5(1):63
pubmed: 34215841
Lipids Health Dis. 2023 Mar 14;22(1):39
pubmed: 36915125
J Eur Acad Dermatol Venereol. 2017 Jan;31(1):e27-e29
pubmed: 26935979
Jpn J Clin Oncol. 2020 Jun 10;50(6):671-678
pubmed: 32129446
Diabetol Metab Syndr. 2022 Nov 14;14(1):169
pubmed: 36376958
Cancers (Basel). 2022 Dec 25;15(1):
pubmed: 36612122
Nat Commun. 2019 Feb 18;10(1):809
pubmed: 30778058
BMC Clin Pathol. 2014 Jun 21;14:27
pubmed: 25093010
Am J Cancer Res. 2016 Jul 01;6(7):1461-93
pubmed: 27508091
J Invest Dermatol. 2011 Mar;131(3):762-8
pubmed: 21085192
Leukemia. 2014 Apr;28(4):880-7
pubmed: 24104394
Acta Derm Venereol. 2022 Oct 04;102:adv00785
pubmed: 35788691
Blood Adv. 2020 Jul 28;4(14):3466-3473
pubmed: 32722786
Anticancer Res. 2014 Dec;34(12):7207-17
pubmed: 25503151
Cancer Biomark. 2017;18(4):339-347
pubmed: 28128734
Hematology. 2020 Dec;25(1):405-413
pubmed: 33191875
Leuk Res. 2011 Feb;35(2):208-13
pubmed: 20570349
Pathol Oncol Res. 2015 Jul;21(3):597-604
pubmed: 25388103
Sci Rep. 2015 Mar 05;5:8801
pubmed: 25739786
Pathol Oncol Res. 2015 Jul;21(3):821-5
pubmed: 25698383
J Hepatol. 2012 Jun;56(6):1371-83
pubmed: 22314424
Cell Death Dis. 2020 Sep 9;11(9):731
pubmed: 32908121
Cancers (Basel). 2020 May 13;12(5):
pubmed: 32414221
Oncol Lett. 2023 Apr 26;25(6):250
pubmed: 37153053
Br J Haematol. 2003 Jun;121(5):681-91
pubmed: 12780782
Cancers (Basel). 2022 Apr 08;14(8):
pubmed: 35454781
Science. 1994 Mar 4;263(5151):1281-4
pubmed: 8122112
Nucleic Acids Res. 2020 Jul 2;48(W1):W521-W528
pubmed: 32374865
FASEB J. 2023 Apr;37(4):e22839
pubmed: 36946075
Int J Mol Sci. 2017 Oct 15;18(10):
pubmed: 29036928
Transl Cancer Res. 2021 Jul;10(7):3548-3559
pubmed: 35116658
Transl Pediatr. 2015 Jan;4(1):4-11
pubmed: 26835354
Leuk Res. 2013 Oct;37(10):1315-21
pubmed: 23915977
Sci Rep. 2019 May 14;9(1):7381
pubmed: 31089163
Medicine (Baltimore). 2018 Oct;97(41):e12743
pubmed: 30313079
Cell Rep. 2016 Aug 16;16(7):1915-28
pubmed: 27498867
Br J Dermatol. 2012 Feb;166(2):331-6
pubmed: 21966986
Leukemia. 2022 Aug;36(8):2050-2063
pubmed: 35676454
Genes Dev. 2004 Jan 15;18(2):132-7
pubmed: 14729570
Diagn Histopathol (Oxf). 2016 Apr;22(4):142-151
pubmed: 29225700
Am J Pathol. 1988 Aug;132(2):265-77
pubmed: 3261136
Sci Rep. 2017 Apr 06;7:46176
pubmed: 28382976
Blood. 2009 Aug 20;114(8):1585-95
pubmed: 19531656
FEBS Lett. 2014 May 2;588(9):1773-9
pubmed: 24685694
PLoS One. 2011;6(11):e27271
pubmed: 22102884
Cancer Res. 2016 Mar 15;76(6):1615-26
pubmed: 26795347
Sci Rep. 2017 Nov 10;7(1):15277
pubmed: 29127370
Leuk Res. 2013 Jun;37(6):647-56
pubmed: 23522449
Nutrients. 2021 Jun 29;13(7):
pubmed: 34210046
Blood Cancer J. 2017 Dec 15;7(12):653
pubmed: 29242582
Int Arch Allergy Immunol. 2018;177(3):207-218
pubmed: 30048989